Abstract
Therapy for Parkinsons disease (PD), a common neurological disorder characterized by pathological degeneration of the nigrostriatal dopaminergic system, remains unsatisfactory. Gene therapy is considered one of the most promising approaches to developing a novel effective treatment for PD. Among the numerous candidate genes that have been tested as therapeutic agents, those encoding tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I and aromatic L-amino acid decarboxylase all boost dopamine production, while glial cell line-derived neurotrophic factor promotes the survival of dopaminergic neurons and is generally believed to possess the greatest potential for successful restoration of the dopaminergic system. The genes encoding vesicular monoamine transporter-2 and glutamic acid decarboxylase have also produced therapeutic effects in animal models of PD. Both viral and non-viral vectors, each with its particular advantages and disadvantages, have been used to deliver these genes into the brain. Whether or not regulatable expression systems are essential to successful gene therapy for PD remains a critical issue in the clinical application of this emerging treatment. Here we review the current status of gene therapy for PD, including the application of control systems for transgene expression in the brain.
Keywords: parkinsons disease, gene therapy, glial cell line-derived neurotrophic factor, viral vectors, tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I
Current Gene Therapy
Title: Gene Therapy for Parkinsons Disease: Progress and Challenges
Volume: 5 Issue: 1
Author(s): Qin Chen, Yi He and Keyi Yang
Affiliation:
Keywords: parkinsons disease, gene therapy, glial cell line-derived neurotrophic factor, viral vectors, tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I
Abstract: Therapy for Parkinsons disease (PD), a common neurological disorder characterized by pathological degeneration of the nigrostriatal dopaminergic system, remains unsatisfactory. Gene therapy is considered one of the most promising approaches to developing a novel effective treatment for PD. Among the numerous candidate genes that have been tested as therapeutic agents, those encoding tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I and aromatic L-amino acid decarboxylase all boost dopamine production, while glial cell line-derived neurotrophic factor promotes the survival of dopaminergic neurons and is generally believed to possess the greatest potential for successful restoration of the dopaminergic system. The genes encoding vesicular monoamine transporter-2 and glutamic acid decarboxylase have also produced therapeutic effects in animal models of PD. Both viral and non-viral vectors, each with its particular advantages and disadvantages, have been used to deliver these genes into the brain. Whether or not regulatable expression systems are essential to successful gene therapy for PD remains a critical issue in the clinical application of this emerging treatment. Here we review the current status of gene therapy for PD, including the application of control systems for transgene expression in the brain.
Export Options
About this article
Cite this article as:
Chen Qin, He Yi and Yang Keyi, Gene Therapy for Parkinsons Disease: Progress and Challenges, Current Gene Therapy 2005; 5 (1) . https://dx.doi.org/10.2174/1566523052997505
DOI https://dx.doi.org/10.2174/1566523052997505 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecule Inhibitors of Peptidylprolyl cis/trans Isomerase
Current Enzyme Inhibition Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Liposome-linear polyethyleneimine-DNA Nanocomplexes for Gene Delivery: Preparation, Characterization and In Vitro Transfection Activity
Current Nanoscience Biological Targets of Antitumor Indolocarbazoles Bearing a Sugar Moiety
Current Medicinal Chemistry - Anti-Cancer Agents An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry A Review of Titanium Di Oxide Nanoparticles - Synthesis, Applications and Toxicity Concerns
Nanoscience & Nanotechnology-Asia Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology The Role of the Osteoimmune Axis in the Inflammation of the Inner Auditory Ear and with Regard to the Putative Anticarcinogenetic Principle: Part 2
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Degenerative Effect of Melatonin on Intervertebral Disc: Protective Contribution against Inflammation, Oxidative Stress, Apoptosis, and Autophagy
Current Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy